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1. Introduction
In this contribution we aim to summarise our
work of recent years and, without seeking to be ex-
haustive, to describe our thinking about the ‘uncou-
pling proteins’ (UCP). We make no apology for our
somewhat partisan point of view, including in the
choice of references, which we expect will be counter-
balanced by other contributors to this special issue.
Mitochondria oxidise substrates and a large part
of the energy released by this process is used by these
organelles to phosphorylate ADP into ATP. The
term coupling summarises the property of mitochon-
dria to adapt their oxidation rate to the energy de-
mand (ATP production). In vitro, the respiratory
rate of a mitochondrial preparation when phosphor-
ylation of ADP is occurring (state 3) is several times
higher than the rate when ADP is exhausted and
therefore no more ATP is produced (state 4). The
respiratory control ratio (state 3 rate/state 4 rate)
quanti¢es the coupled state of mitochondria. Dam-
aged mitochondrial preparations show uncoupling
and their ATP production is severely compromised.
In vivo, uncoupled mitochondria are expected to be
of ‘no value’ and even worse to be deleterious since
they would dissipate metabolic energy and compro-
mise ATP production. Yet they would produce heat
and oxidise reduced coenzymes, two activities that
could have a positive value per se. In living organ-
isms, fermentation suggests the need for oxidation,
whereas the adaptive thermogenesis occurring in the
brown adipose tissue of mammals illustrates the need
for adaptive thermogenesis.
The term UCP was introduced to describe the 32
kDa protein found in brown adipose tissue mito-
chondria, now the term UCP1 is used (see below).
In the presence of UCP1, a high respiratory rate
occurs in the absence of ATP production, and this
could be explained by the high permeability of the
mitochondrial inner membrane to protons when
UCP1 is active. However, UCP1 is also able to trans-
port various anions [1] and is not exclusively a pro-
ton transporter (reviewed in [2], see also [3]). This led
to disagreement about the exact mechanism used by
UCP1 under physiological conditions [4^6]. Some
authors consider that UCP1 is not a proton trans-
porter at all and that proton transport is an indirect
consequence of anion transport [4] (Fig. 1). Never-
theless, the presence of large quantities of UCP1 en-
ables a rapid back£ow of protons through the mito-
chondrial inner membrane, and therefore proton
pumping by the mitochondrial respiratory chain can-
not generate a proton electrochemical gradient high
enough to suppress substrate oxidation. Respiratory
control is therefore lost, and large quantities of sub-
strates are burned without energy conservation.
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Therefore, heat production in the brown adipocytes
is intense. A stringent control on UCP1 gene expres-
sion, and a direct control of the activity of the pro-
tein itself, ensures that this energy dissipative path-
way operates when thermogenesis is needed. UCP1 is
able to bind nucleotides and nucleotide binding in-
hibits its uncoupling (transport) activity, whereas free
fatty acids increase it. This is physiologically apt,
since ‘at rest’ in brown adipocytes endogenous nu-
cleotides would keep UCP1 inactive, whereas stimu-
lation of adipocytes triggering lipolysis would release
fatty acids used as fuels for the uncoupled respiration
resulting from UCP1 activation. These issues were
addressed in the 70s and early 80s, reviewed in
[7,8]. More recently the construction of mice
knocked-out for the ucp1 gene has proved the crucial
role of this protein in the regulatory thermogenesis
necessary for mice to cope with a low ambient tem-
perature [9].
Since 1997 genes encoding proteins closely related
to the 32 kDa protein of brown adipose tissue mito-
chondria were discovered [10^14], and therefore the
term UCP has been changed into UCP1 to refer to
the brown adipose tissue mitochondrial UCP, where-
as the terms UCP2, UCP3 have been introduced for
the closest homologues. It was proposed that these
proteins share also functional similarities with UCP1,
and therefore would also be able to induce uncou-
pling of respiration.
2. Molecular studies on UCP1
2.1. Cloning
UCP1 was found to have the interesting property
of being expressed only in specialised cells called
brown adipocytes, constituting the brown adipose
tissue of mammals. This peculiarity made the study
of this protein and of its gene exceptionally attractive
and, moreover, easier in several respects. The early
cloning of a cDNA for UCP1 was possible because
of its exceptionally high expression in brown fat, and
with the help of the inducible character of its mRNA
[15]. The cDNA indicated the complete sequence
UCP1 [16], and direct amino acid sequencing unrav-
eled UCP1’s primary structure [17].
2.2. Sequence analysis
Analysis of its amino acid sequence showed that
UCP1 is organised as a triplicated structure [17]. This
was initially observed with a partial sequence of the
ADP/ATP translocator [18]. Many transporters
found in the mitochondrial inner membrane share
this property, and they constitute a large family of
homologous proteins [19,20]. More speci¢c sequences
attracted our attention in UCP1. A stronger homol-
ogy with the ADP/ATP carrier was found in the
Fig. 1. Di¡erent mechanisms proposed to explain situations
where uncoupling of mitochondria is observed. The mitochon-
drial anion carrier protein inserted in the mitochondrial inner
membrane (grey rectangle) is shown with two functional do-
mains (see Fig. 2). The orientation of the membrane potential
is indicated. To uncouple mitochondrial respiration, the protein
could behave as a proton transporter (top). In the fatty acid cy-
cling model (middle), the protonated fatty acids that move
freely in the lipid phase of the membrane undergo de-protona-
tion on the inner side of the membrane. The anionic form of
the fatty acid is then driven back to the outer side by the mito-
chondrial carrier, where this fatty acid anion can be protonated,
and a new cycle starts. Finally, a loss of the speci¢city of trans-
port (bottom), likely to involve the gating domain of the car-
rier, could lead to uncoupling. In the more extreme case, modi-
¢cation of the structure of the carrier allows solutes of 1000 Da
to cross the membrane through the pore constituted by the
modi¢ed carrier.
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third (C-terminal) domain of the protein. Since
UCP1 is able to bind nucleotides, and the ADP/
ATP carrier transports them, it was proposed that
the C-terminal domain is involved in the interaction
between UCP1 (or the translocator) and nucleotides
[16]. Thereafter it was noticed that a short sequence
(amino acids 261^269 in rat UCP1) was shared be-
tween UCP1, the translocase and the DNA binding
domain of several transcription factors [21]. These
intriguing homologies prompted us to initiate a re-
combinant expression programme with the aim of
studying the possible involvement of these amino
acids in the regulation of the activity of UCP1, using
site-directed mutagenesis.
2.3. Setting up a bacterial expression system
Since the primary aim was to determine whether a
limited domain of UCP1 would be su⁄cient to pro-
mote nucleotide binding, we started with an expres-
sion system where subdomains of UCP1 could be
produced and puri¢ed. We chose to use mal-E-based
fusion proteins produced in Escherichia coli. From
this source mal-E fusion proteins could be easily pro-
duced and puri¢ed, but binding experiments would
prove inconclusive. However, it became apparent
that these fusion proteins were readily recognised
by anti-UCP1 antibodies and could be used for a
topological study of UCP1 in the mitochondrial in-
ner membrane [22], and thus a fairly complete topo-
logical map of UCP1 was produced [23]. This work
on UCP1 is probably still the strongest experimental
evidence in support of the theoretical model pro-
posed for mitochondrial carrier proteins with six
transmembranous K helices (Fig. 2).
2.4. Recombinant mammalian cell line: UCP1 in
mitochondria
An expression vector for UCP1 was introduced in
a mammalian cell line in order to observe whether
the introduction of UCP1 into mitochondria is su⁄-
cient to reproduce the uncoupled phenotype ob-
served in brown adipose tissue mitochondria. How-
ever, in contrast with many studies involving
transfection of mammalian cell lines, transient trans-
fection procedures could not be used since the study
of mitochondrial preparations required homogenous
starting material, and therefore the tedious isolation
of stable transformants was unavoidable. As ex-
pected, introduction of the UCP1 expression vector
in CHO cells produced a new cell line expressing
UCP1 in mitochondria. When these mitochondria
were studied in vitro, they showed a spontaneously
uncoupled state, which was restored to a coupled
state by addition of GDP. Therefore, introduction
of UCP1 in mammalian cells by genetic manipula-
tion was su⁄cient to reproduce the mitochondrial
alteration observed in brown fat [24]. This observa-
tion complemented the work done with puri¢ed
UCP1 in reconstitution experiments designed to
demonstrate its activity as a passive proton trans-
porter [25^28]. This ¢rst establishment of a recombi-
nant expression system for a functional UCP1
opened the way to the use of site-directed mutagen-
esis studies on UCP1.
2.5. The yeast expression system
The expression of wild-type UCP1 was well toler-
ated by the CHO cell line. This was ascribed to the
fact that within these cells endogenous levels of nu-
Fig. 2. Two di¡erent representations of a mitochondrial carrier.
Topology (top): UCP1 is shown in the inner membrane, the re-
gions recognised by non-permeant macromolecular probes like
antibodies are shown protruding above or below the grey rect-
angle representing the mitochondrial inner membrane. Rectan-
gles represent K helices. Functional domains (bottom): the
channel domain (open rectangles) would constitute a pathway
through the membrane whereas the gating domain (dark grey
polygon) would determine the speci¢city of transport.
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cleotides would keep UCP1 partially or completely
inhibited and therefore cellular bioenergetics were
not compromised by this UCP. However, with a
view to producing mutant proteins with altered prop-
erties, it was postulated that a facultative aerobic
organism like yeast would be of value. As a micro-
organism, yeast would produce more of the protein,
which was expected to reach yeast mitochondria and
fold naturally, unlike in bacteria where recombinant
proteins accumulate as inclusion bodies. We there-
fore accepted with enthusiasm the proposal of Dr
Rial to collaborate on the recombinant expression
of UCP1 in yeast. Yeast o¡ered another crucial ad-
vantage over other eukaryotic cells: very good induc-
ible/repressible vectors were available and this is of
crucial importance in selecting and maintaining re-
combinant strains containing an expression vector
encoding a potentially deleterious protein.
2.6. The YUP (YMUC) incident
Although the basis of the yeast expression system
was sound, an unexpected complication arose. Ex-
periments designed to check the e¡ects of nucleotides
on yeast mitochondria revealed the existence of an
endogenous uncoupling pathway [29], the activity of
which could result in a complete uncoupling of res-
piration in vitro. To overcome this complication, we
studied this pathway’s characteristics in detail, and
found that it (called YUP for yeast uncoupling path-
way) is an uncoupling pathway sensitive to the ATP/
ADP+Pi ratio [30,31]. ATP promotes uncoupling;
ADP and inorganic phosphate are inhibitors. Con-
sequently, media containing high phosphate concen-
trations (5^10 mM) had to be used to obtain yeast
mitochondria where YUP is inhibited and where
UCP1 activity could be studied. The essential char-
acteristics of YUP regulation have been con¢rmed by
others, although they called it ‘YMUC’ [32,33].
2.7. UCP1 at work in yeast
Once YUP is inhibited by phosphate, it is possible
to observe the activity of UCP1 in recombinant yeast
mitochondria. This was true with isolated mitochon-
dria [34] and with permeabilised spheroplasts (M.
Goubern and F. Bouillaud, unpublished data).
Many mutants of UCP1 have been studied in this
system, including mutants of the domain mentioned
beforehand. Although this domain was shown to be
required for nucleotide inhibition [35], it became ob-
vious that it has some more general importance in
UCP1. Removal of this domain produced a mutant
protein which allows the passage of very large solutes
(up to 1500 Da). This limit is very similar to that of
the so-called mitochondrial transition pore, a struc-
ture in which the ADP/ATP translocator is thought
to play a key role, reviewed in [36]. Therefore it is of
interest to notice that deletion of this domain, which
is similar in UCP1 and in the ADP/ATP transloca-
tor, led to the conversion of UCP1 into such a pore.
UCP1 (like other carriers) has a triplicated structure,
there are therefore two other related domains in the
protein. In subsequent mutagenesis studies it was
shown that these three domains participate similarly
in the control of transport by UCP1 [37]. Fig. 3 out-
lines how such similarity may be found between the
structure of mitochondrial carriers and the functional
division of the carrier activity into channel and gat-
ing domains.
Experiments using plates or in liquid culture
showed that induction of expression of UCP1 in
yeast resulted in a lower growth rate [35,37,38]. It
was of interest to observe that the addition of fatty
acids to the culture medium further increased the
generation time and that this increase was dependent
Fig. 3. The localisation of mutations introduced in UCP1 is
shown on the topological domain, whereas the interpretation in
functional terms is given at the bottom. This obviously suggests
that the topological map and the functional domains coincide
to some degree, which is made apparent by the similarity of the
schemes used for topological and functional representations.
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on mutations in the UCP1 sequence [38]. The fatty
acid bromopalmitate was used as a non-metabolis-
able derivative, but experiments using plates showed
that other fatty acids like linoleic acid (Rial et al.,
unpublished data) could be used.
Changes in yeast mitochondrial membrane poten-
tial due to UCP1 activity were examined using £uo-
rescent probes (i.e. DiOC(6)3) which accumulate in
the organelle in response to membrane potential. It
should be noted that yeast needs concentrations of
the DiOC(6)3 probe (100 nM) that are two orders of
magnitude higher than the concentrations recom-
mended for mammalian cells [39]. This is due to
the presence of the cell wall, which constitutes a bar-
rier to probe di¡usion. Expression of UCP1 is ac-
companied by a decrease in labelling with the
DiOC(6)3 probe. Induction with galactose lasted
for several hours before analysis by £ow cytometry,
and so there is a risk that what we observed is a
delayed consequence of the induction, including
modi¢cation of mitochondrial structure rather than
a mere recording of membrane potential. Note that
there are cases of recombinant expression of mito-
chondrial carriers that do not disturb yeast growth
or DiOC(6)3 labelling, examples being the oxogluta-
rate carrier ([40] and Fleury et al., unpublished data).
This is also true for UCP1 mutants, although during
tests in vitro they still show a fatty acid stimulation
and nucleotide inhibition of proton leak [37]. Distur-
bance of yeast bioenergetics is therefore not an obli-
gatory consequence of recombinant expression of a
mitochondrial carrier, and mutated forms of UCP1
could be completely inhibited under the intracellular
conditions. Decreased growth rate and reduced
DiOC(6)3 labelling strongly suggest that the trans-
port activity of the newly introduced protein alters
mitochondrial membrane potential and/or mitochon-
driogenesis. Good correlation was observed between
the £uorescence decrease measured by £ow cytomet-
ry, growth rate modi¢cation and the uncoupling e⁄-
ciency of the protein observed in isolated yeast mi-
tochondria ([35,37] and Fleury et al., unpublished
data).
2.8. The control of ucp1 gene expression
The ucp1 gene is expressed exclusively in brown
adipocytes, and its expression is highly inducible.
Cyclic AMP [41] and retinoic acid [42,43] are two
powerful inducers of ucp1 gene transcription. An in-
crease in cyclic AMP results from adrenergic stimu-
lation of brown adipocytes which occurs upon cold
exposure, but the physiological role of retinoic acid is
more obscure. Studies combining in vivo (cell trans-
fection, transgenic mice) and in vitro (gel shift assays,
DNA footprinting) experiments have been undertak-
en to unravel the genomic regions controlling the
expression of the ucp1 gene speci¢cally in brown
fat, and its response to neurohormonal stimulation.
It was shown that the 4.5 kb located in front of the
transcription start site of the ucp1 gene were able to
drive the expression of a reporter gene with charac-
teristics identical to the endogenous ucp1 gene [41].
Further investigation showed that the qualitative
characteristics of the rodent ucp1 gene are contained
within a 211-bp element located about 2 kb upstream
from the transcription site [44]. This property is illus-
trated in transgenic mice where the 211-bp element is
inserted in front of a viral promoter driving the tran-
scription of a reporter gene [45]. This reporter gene is
expressed exclusively in brown fat where it responds
to stimuli like the endogenous ucp1 gene. Since in
these experiments the 211-bp element confers on
the viral promoter the essential properties of the
ucp1 gene promoter region, it is concluded that
most of the relevant properties of the ucp1 promoter
are clustered within this 211-bp element, and future
studies will therefore aim to de¢ne the trans-activat-
ing factors interacting with this 211-bp DNA se-
quence.
2.9. UCP1 in humans
The human ucp1 gene was cloned, and this allowed
probing for the expression of UCP1 mRNA in hu-
mans [46], as well as genetic studies to examine to
what extent the ucp1 gene is implicated in energy
expenditure and body weight control in man. A
polymorphic site was discovered in the human ucp1
gene. This is due to a single base change in the pro-
moter sequence of the ucp1 promoter sequence lead-
ing to the disappearance of a BclI restriction site, this
allelic form is present in about 25% of the human
ucp1 genes [47]. Data from the study of this poly-
morphism suggest that the ucp1 gene is not a major
obesity gene, but may participate with other genes in
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predisposing to fat accumulation [48]. Increase in
body weight over a 12-year period was correlated
with this BclI polymorphism of the ucp1 gene [47].
This is wholly in line with the idea that a marginal
increase/decrease in energy expenditure due to UCP1
would result over time in a smaller/larger increase in
body weight, rather than being a determinant of the
body weight itself. As a mirror image of this study, a
correlation was found between this polymorphism of
the ucp1 gene and the resistance to weight loss during
hypocaloric diet [49]. The human ucp1 gene promoter
has been isolated and its transcriptional regulation
has been studied. This revealed a situation similar
to that of rodents since retinoic acid, norepinephrine
(cyclic AMP), and thiazolidinedione are activators of
transcription. However, in contrast with the rodent
(rat, mice) ucp1 gene, the transcriptional activation
of the human ucp1 promoter by cyclic AMP was
found to be strictly dependent on retinoic acid pres-
ence [M.M. Gonzalez-Barroso, C. Pecqueur, C.
Gelly, D. Sanchis, M.C. Alves-Guerra, F. Bouillaud,
D. Ricquier, A.M. Cassard-Doulcier, J. Biol. Chem.
275 (2000) 31722^31732].
3. Cloning new homologues of UCP1
3.1. UCP2 and UCP3
Evidence gradually accumulated for the existence
of close homologues of UCP1. For various reasons
this was not examined for a long time, probably
because these reports invariably led their authors to
conclude that UCP1 was not just expressed in brown
fat [50,51], although this proved erroneous in some
cases [52]. We decided to seek homologues of UCP1
in a mouse muscle cDNA library and found a clone
called UCP-like, which was later renamed UCP2
[10]. Other groups meanwhile had cloned UCP2
[14] and/or UCP3 [11^13]. The sequences of UCP1,
UCP2 and UCP3 were highly similar, suggesting
common properties in addition to being members
of the ‘mitochondrial anion carrier family’ (Fig. 4).
For example, alignment analysis suggests that the
distance between the UCP1, UCP2 and UCP3 se-
quences is shorter than the distance between mam-
malian and yeast adenine nucleotide translocases
(Fig. 4). Conservation of the di¡erent sequences is
slightly variable, and according to the Unigene data-
base (www.ncbi.nlm.nih.gov/UniGene) the percent-
age similarity between human and rodent (rat and
mouse) UCP1 sequences is 79%; it is 85% for
UCP3 and it rises to 95% for UCP2. Conclusions
concerning the biochemical activities of UCP2 and
UCP3 have to be supported by experimental data.
At this point it should be borne in mind that the
transport properties of these proteins examined in
reconstituted or recombinant systems do not auto-
Fig. 4. This tree indicates the similarities between several mito-
chondrial carriers. The length of horizontal branches is propor-
tional to the divergence between amino acid sequences of the
di¡erent proteins. The sequences were collected at the Nation-
al Center for Biological Information (NCBI) database
(www.ncbi.nlm.nih.gov). Human sequences of the dicarboxylate,
2-oxoglutarate, citrate, ornithine, carnitine and phosphate car-
riers as well as isoforms of the ADP/ATP translocator (ANT1^
3 Hs) were compared to human UCP1^4 and BMCP1 sequen-
ces. There are two isoforms of the phosphate carrier (A and B)
produced by an alternative splicing. The Clustal W was used to
generate alignment and the guide ¢le (dnd) used to draw the
tree with the NJplot software. To estimate a maximum distance
between proteins with the same biochemical activities in two
di¡erent organisms the ADP/ATP translocases of the yeast Sac-
charomyces cerevisiae (ANT1^3 Sc) have also been introduced.
The dotted segment corresponds to the divergence between hu-
man and yeast ADP/ATP translocases. This same segment is
represented close to the UCPs. The purpose of this ¢gure is
only to compare these distances, not to de¢ne the evolutionary
relationships between carriers, because the introduction of yeast
ANT sequences modi¢es signi¢cantly the shape of the tree in
comparison with the shape obtained with human sequences
only.
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matically lead to more pertinent conclusions con-
cerning their physiological role. For example, chlo-
ride transport by UCP1 is supported by much solid
experimental evidence noted with brown adipose tis-
sue isolated mitochondria [1,2] or in reconstituted
systems [3,53], but is of little help understanding
the physiological relevance of UCP1. The physiolog-
ical relevance of the potentially various activities of
such proteins is a complicated issue: for example
interactions with various intracellular regulators
could cancel out some activities observed in vitro
or reveal others not yet observed in arti¢cial systems.
3.2. BMCP1 and UCP4
The existence of a further homologue expressed in
the central nervous system was postulated on the
basis of expressed sequence tags and according to
several hybridisation signals. As can be seen in Fig.
4, this additional homologue is more distantly related
to UCP1 than are UCP2 and UCP3, and for this
reason we ¢nally called it BMCP1 [54]. Another ho-
mologue termed UCP4 is also expressed in brain [55].
3.3. Expression patterns and chromosomal location
To date, ¢ve genes have been identi¢ed in mam-
mals: UCP1, UCP2, UCP3, BMCP1, and UCP4
(Fig. 4). Gene mapping shows that the ucp2 and
ucp3 genes are a few kb apart [56], and probably
emerged from a gene duplication event. The chromo-
somal localisation of the ucp2 ucp3 cluster is 11q13
between D11S916 and D11S911 in humans and chro-
mosome 7 in mice [10]. BMCP1 is located on the X
chromosome (Xq25^26) in man, between the genetic
markers DXS1206 and DXS1047, and has been
cloned from clone dJ20I3 from the Sanger Centre
(D. Sanchis, personal communication). UCP4 has
been mapped on 6p11.2^q12 close to the genetic
marker SHGC-34952 [55].
The expression pattern of these genes, based on
mRNA detection, has been evaluated in various pub-
lications and reviewed [57^59]. Brie£y, UCP3 mRNA
is found in skeletal muscle and also in brown adipose
tissue. BMCP1 and UCP4 are predominantly ex-
pressed in neural tissues, namely the brain [54,60].
UCP2 is more ubiquitous but mRNA levels di¡er
greatly from one organ to another. UCP2 is highly
expressed in spleen, for example, but levels are low in
liver. Organs involved in immune defence, or rich in
macrophages, express abundant UCP2 mRNA. Sev-
eral lines of evidence point to speci¢city of UCP2
expression in several cell types but not in others,
see for example [61,62]. Variations in UCP2 and
UCP3 mRNA levels have been correlated with di¡er-
ent physiological states, reviewed in [57^59]. Numer-
ous studies indicate that expression of UCP2 and
UCP3 is stimulated by thyroid hormones, and also
in the presence of high levels of fatty acids. This
leads to patterns of expression inconsistent with a
role in promoting energy expenditure, since starva-
tion, which promotes the use of fatty acids but de-
creases energy expenditure, induces an increase in
mRNA levels of UCP2 and UCP3. It should be re-
called, however, that almost all publications are
based on mRNA levels, which are not always con-
sistent with levels of mitochondrial proteins [63] or
possibly of UCPs [64] (Pecqueur et al., in prepara-
tion). Furthermore, we now feel that the speci¢city of
antibodies used [64^69] may not have been examined
carefully enough (Pecqueur et al., in revision).
3.4. A plant UCP
A plant homologue of UCP1 obtained from Sol-
anum tuberosum (StUCP) has been studied in the
yeast expression system [70]. A fascinating character-
istic of StUCP is its induction by cold exposure of
plants, which is reminiscent of the control of UCP1
expression in brown adipose tissue [70]. The existence
of such a protein had been postulated on the grounds
of experimental evidence obtained with isolated mi-
tochondria from S. tuberosum tubers [71], and the
authors of this report used the term PUMP (for
plant uncoupling mitochondrial protein). Despite
several attempts, we were unable to reproduce the
experiment presented in the original paper [71] de-
scribing a re-coupling of mitochondria with nucleo-
tides, as this re-coupling, if present, was masked by
the activation of mitochondrial respiratory chain by
nucleotides (M. Goubern and F. Bouillaud, unpub-
lished data), suggesting a problem in the choice of
the variety of plants used. The activity and physio-
logical relevance of the plant UCP (PUMP) is being
studied by other authors in parallel with the activity
of the alternative oxidase found in plants, since both
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are expected to participate in re-oxidation of coen-
zymes independently of ATP generation [72].
3.5. Others
As is apparent from the work with plants, such
sequences are not limited to mammals or homeo-
therms. Homologues have been described in proto-
zoa [73], fungi [74], and ¢shes [75], although the mo-
lecular characterisation is not always complete. This
widespread occurrence certainly questions the role of
such proteins in thermogenic processes, but it would
be an over-simpli¢cation to consider the uncoupling
of mitochondria solely in terms of heat production.
4. Activities of these homologues
4.1. A quick review of the role of ‘uncoupling’
It has long been postulated that some mitochon-
drial uncoupling may be advantageous for eukary-
otic cells (for a recent review [76]). Some mitochon-
drial uncoupling is taken to mean a proton
conductance of the inner membrane clearly above
the minimum observable value. It should be recalled
that in state 4, the membrane potential would rise to
200 mV, thereby generating an electrical ¢eld of al-
most 105 V per cm. A non-speci¢c leak of protons
across inner membrane is therefore not unlikely. Pro-
ton conductance is increased by hyperthyroidism [77]
and phylogeny [78], for example. These observations
thus argued for some mechanism able to increase the
proton conductance of the inner membrane in a
regulated manner. The unexpected occurrence of
the YUP phenomenon in yeast [29] alerted us to
the existence of such mechanisms.
Why should such regulated mechanisms be bene¢-
cial to the organism when they would lead to energy
loss? Possible roles included thermogenesis, regula-
tion of metabolic processes (a possible dissociation
between re-oxidation of coenzymes and oxidative
phosphorylation), and last but not least the control
of oxygen radical production in the mitochondrial
respiratory chain. In state 4 (no ATP production),
the reduced respiratory chain and the high mem-
brane potential would increase oxygen radical pro-
duction at the level of the Q cycle. Accordingly it has
been proposed that mild uncoupling would be a
mechanism to reduce the membrane potential and
therefore superoxide ion production at the mitochon-
drial level [76]. In this respect, partial uncoupling and
the accompanying loss of energy would be ‘a price
worth paying’ to increase ‘metabolic £exibility’ or to
avoid poisoning by oxygen radicals when the ATP
demand is low.
Several suggestions have been made for the possi-
ble mechanisms involved in this process. A role of
the fatty acid composition of phospholipids of the
inner membrane was shown to be unlikely [79], and
proteins are therefore likely to be involved. Experi-
mental evidence shows that proteins normally acting
in an ‘energy conservative manner’ could under cer-
tain experimental conditions lead to uncoupling and
energy waste [76,80,81]. The best example would be
the adenine nucleotide translocase, which promotes
the fatty acid cycling mechanism and is likely in-
volved in the mitochondrial permeability transition
pore. However, the extent to which these activities
observed in vitro are recruited in the cellular context
is a matter of debate. The discovery of sequences so
close to a ‘physiologically relevant’ UCP, and show-
ing such activity in the functional tests conducted so
far [10,40,82,83], made the hypothesis of specialised
genes being involved in such control of the proton
permeability of the inner membrane very attractive.
Accordingly, it was proposed very early that UCP2 is
involved in the control of oxygen radical production
[61].
4.2. The uncoupling activity of these proteins
The ¢rst issue to examine is whether these proteins
have an uncoupling activity. Although simple in
principle, this is a di⁄cult issue in practice. As noted
above, the observation of uncoupled mitochondria
strongly suggests damage of these organelles during
preparation, and in refuting such an explanation it is
advisable to present data indicating that some phys-
iologically relevant parameters would regulate the
uncoupling state. A ¢rst simpli¢cation would be to
consider that the uncoupling activity has to be regu-
lated like the activity of UCP1. Accordingly, mito-
chondria where such a UCP is expected to be present
are examined for some fatty acid-induced uncoupling
and/or nucleotide-induced re-coupling. In fact such
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tests are full of complications because it has long
been known that the uncoupling e¡ects of fatty acids
on mitochondria are likely to be explained at least
partially by interaction between fatty acids and mem-
bers of the mitochondrial carrier family other than
UCPs, reviewed in [76,80]. A carrier heavily involved
in these e¡ects is the adenine nucleotide translocase,
and further complicates matters since this protein
obviously also interacts with nucleotides. It is still a
matter of debate whether the fatty acid cycling due
to such a mitochondrial carrier is of any physiolog-
ical relevance. This indicates that the uncoupling ob-
served after addition of compounds like fatty acids
might be a side e¡ect of a ‘non-UCP’ carrier protein
conserved by natural selection for other purposes.
Therefore, reconstitution of the cycling phenomenon
in phospholipid vesicles containing UCP2 and UCP3
is not that informative regarding their physiologically
relevant activity [84]. On the other hand, when mi-
tochondrial preparations are used, the assumption
that fatty acid stimulation of mitochondrial respira-
tion and/or its inhibition by nucleotides is possibly
attributable to the UCP homologue thought to be
present in the mitochondrial membrane deserves
more thorough examination. Controversial data
have been reported concerning correlation between
the expression level of UCP2 or UCP3 and the pro-
ton leak of the inner membrane [68,85,86].
Although the yeast expression system was used
mainly for historical reasons, we think it has several
advantages compared to ‘natural mitochondria’ and
to ‘arti¢cial vesicles’ where a puri¢ed protein is in-
troduced. Recombinant yeasts have the great advan-
tage of providing close control, since mitochondria
from yeast grown under the same conditions but
containing an empty expression vector are used as
control, and therefore we expect to compare mito-
chondria di¡ering only by the presence of a UCP.
However, we are still in a mitochondrial context,
and so the high and sustained membrane potential
generated by the respiratory chain is present. Experi-
ments should be conducted within physiological lim-
its to keep mitochondria active and at least partially
coupled.
4.3. UCP2, UCP3 and BMCP1 in recombinant yeast
Several groups have successfully expressed the
UCPs in yeast and their results are consistent with
the in vivo and in vitro uncoupling activity of these
homologues [10,40,82,83,87]. In our hands, the in-
duction of UCP2 expression in yeast resulted in a
lower growth rate and decreased staining with the
DiOC(6) probe, indicating a likely decrease in mito-
chondrial membrane potential and at least demon-
strating a mitochondrial e¡ect [10]. Studies with iso-
lated mitochondria showed that when UCP2 is
present, mitochondria are less coupled than in its
absence [87]. The simultaneous measurement of res-
piratory rate and of mitochondrial membrane poten-
tial in permeabilised yeast spheroplasts showed that
the proton conductance of the mitochondrial inner
membrane is increased when BMCP1 is expressed
[54]. Qualitatively similar results were obtained with
UCP2 (M. Goubern and F. Bouillaud, unpublished
data). A semi-quantitative analysis indicates that the
e¡ects of UCP3 on yeast in vivo are greater than the
e¡ect of UCP1, the reverse being true with isolated
mitochondria [40], a situation that is also likely to be
the case for UCP2 (compare [10] and [87]). This
could be explained by various facts, such as the con-
stitutive inhibition of the wild-type UCP1 by endog-
enous nucleotides, the presence in yeast of endoge-
nous activators of UCP2 or UCP3, and a di¡erent
speci¢city for the transported solutes. We should
stress also that our experiments with yeast mitochon-
dria were done in the presence of a high phosphate
concentration and this may alter the activity of a
‘UCP’ in the not so unlikely eventuality that such a
protein’s activity is in£uenced by the ATP/ADP+Pi
ratio. It remains to determine whether the uncou-
pling activity observed in yeast is maintained/relevant
in a mammalian cell. Unfortunately, there are as yet
very few published data on recombinant mammalian
cells stably expressing UCP1 homologues [88].
4.4. Regulation of the uncoupling activity
It is very likely that the uncoupling activity of
these proteins is under control within the cell. This
is probably obligatory in the case of a protein like
BMCP1 since the proton permeability increase con-
ferred by this protein on the yeast inner membrane is
so high [54] that it seems to us incompatible with
neuronal survival. Mechanisms have therefore to be
proposed to maintain the uncoupling activity under
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control inside the cell. A ¢rst explanation would be
that all the uncoupling e¡ects observed so far are
experimental artefacts, a point of view that would
lead us to consider with suspicion quite a signi¢cant
part of the literature describing reconstituted or re-
combinant expression systems. A second explanation
would be that the uncoupling e¡ects are no more and
no less signi¢cant than the other uncoupling e¡ects
of mitochondrial carriers explored so far. In this re-
spect UCPs would be highly specialised transporters
(since they are not present in all mitochondria), per-
haps more prone to induce uncoupling given their
higher homology with UCP1, which is specialised
for uncoupling and thermogenesis. Keeping these
considerations in mind, several mechanisms could
be proposed and need to be explored to con¢rm or
refute the physiological relevance of their uncoupling
e¡ects. For example, the uncoupling e¡ect is likely to
be heavily in£uenced by the amount of protein
present, and in this respect the signi¢cant or dramat-
ic uncoupling e¡ect recorded in yeast could be as-
cribed to a high expression level, not far from (but
still lower than) the amount of UCP1 present in
brown adipose tissue (E. Rial, I. Arechaga, personal
communication). In brown adipose tissue, UCP1
could account for as much as 5% of mitochondrial
proteins, although there is probably more UCP1
than is needed to uncouple brown fat mitochondria.
Quantitative measurement of UCPs in tissues is in its
infancy, and where UCP levels are much lower than
the UCP1 level in brown fat, the metabolic relevance
of the UCPs would have to be downgraded propor-
tionally (Pecqueur et al., in preparation). This would
not rule out a signi¢cant role of the uncoupling ac-
tivity in specialised processes.
4.5. Retinoids and proton transport by UCP1 and
UCP2
The description of certain retinoids as positive reg-
ulators of the UCP2 uncoupling activity in a pH-de-
pendent manner [87] strengthened the idea of this
uncoupling activity being more than an in vitro arte-
fact. Its speci¢city ¢ts with the characteristics of pro-
tein catalysis and rules out a mere damaging of the
mitochondrial inner membrane by a foreign protein,
and the pH e¡ect is well in line with the intracellular
e¡ect of a pH rise leading to an increase in metabolic
activity [89]. According to the results obtained in the
yeast expression system, UCP2 proved to be regu-
lated di¡erently than UCP1. In contrast with what
was observed with UCP1, the presence of UCP2 did
not markedly increase the sensitivity of yeast mito-
chondria to fatty acid uncoupling. Moreover, the
basal or retinoid-stimulated uncoupling e¡ect of
UCP2 could not be inhibited by nucleotides.
The discovery of retinoids as activators of UCP2
stems from the work on UCP1 and ucp1 gene tran-
scription. Since retinoic acid was a strong inducer of
ucp1 gene expression, it was considered that it may
also activate proton transport by UCP1. Retinoic
acid signalling would therefore constitute a second
complete stimulation pathway for brown adipose tis-
sue thermogenesis, alternate or supplementary to the
noradrenaline/cyclic AMP pathway. Analogies have
been drawn between UCP1 and bacteriorhodopsin
on the grounds of the mechanism of proton or chlo-
ride transport [26], and therefore the activation of
UCP1 and UCP2 by retinoids would support further
the hypothesis of some similarity in the molecular
mechanisms underlying ion transport in these pro-
teins. This retinoid sensitivity of UCP1 and UCP2
could be seen as a primitive property of both pro-
teins, UCP1 having evolved towards a broader spe-
ci¢city so that fatty acids became activators, and this
was associated with a much higher sensitivity. This
means on the other hand that UCP2 is relatively
insensitive, which could mean that proper activators
are still to be found. In fact, our experiments may
suggest that the maximal rate obtained in the pres-
ence of UCP2 is higher than with UCP1, see ¢gure
3B in [87]. This interaction between UCP2 and reti-
noids might also reveal a role in intracellular cell
signalling [87].
Still these experiments do not tell us whether or
not this uncoupling activity is of any help/impor-
tance in the mammalian organism. Again the various
transport activities recorded for UCP1 illustrate the
di⁄culty in drawing physiological conclusions from
these in vitro experiments, although they are of in-
valuable help in understanding the molecular mech-
anisms underlying ion transport by membranous
proteins. The study of genetically engineered mam-
mals where ucp genes would be either speci¢cally
destroyed or overexpressed is expected to shed
more light on their physiological relevance. Alterna-
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tively, human genetics data may indicate the rele-
vance of these loci to di¡erent diseases or to quanti-
tative variations in genetically heritable traits.
4.6. Human genetics, gene microarrays, and
knock-out (KO) mice
A genetic study involving the use of microsatellites
in humans showed that the chromosomal region con-
taining ucp2 and ucp3 genes is linked to the basal
metabolic rate [90]. This is certainly not a demonstra-
tion of their uncoupling activity but on the other
hand it does support the hypothesis of the relevance
of these genes in the genetic determination of the
basal metabolic rate. Many other reports (reviewed
in [59]) have sought to relate metabolic disorders like
obesity or diabetes to the ucp2 ucp3 locus. As no
clear pattern emerged from these studies, it is antici-
pated that ucp2 and ucp3 genes do not play a major
role in the determination of body weight. The linkage
between ucp2 ucp3 locus and anorexia nervosa indi-
cates either how circumstantial these linkage studies
may be, since the chromosomal region studied con-
tains ucp2, ucp3, as well as many (tens?) of other
genes, or alternatively it may suggest that the rele-
vant traits have yet to be discovered.
A second piece of evidence suggests that the im-
portance of UCP2 might be di¡erent from what we
expected in the ¢rst instance. Two cell lines were
derived from the same B lymphoma tumour: one is
resistant and the other is sensitive to radiation-in-
duced apoptotic cell death. Using microarrays to de-
tect genes transcribed di¡erently in response to irra-
diation in both cell lines, it appeared that the
sensitive cells induce expression of the UCP2
mRNA whereas resistant cells do not [91]. This ex-
pression is an early event occurring before any mito-
chondrial dysfunction could be detected. This obser-
vation makes ucp2 a gene likely to be involved in the
cellular response to stress, either in an ultimate at-
tempt to survive, or by participating in the pro-
gramme of apoptotic cell death.
Developments in the ¢eld of KO mice are very
recent. Mice knocked-out for UCP3 have been pro-
duced in Dr Reitman’s [92] and Dr Lowell’s [93]
laboratories. Both reports are consistent with the
original hypothesis that UCP3 behaves as a proton
transporter since it was shown that the proton con-
ductance of the inner membrane of isolated muscle
mitochondria is decreased in UCP3 KO mice [92], or
that the respiratory control and the production of
oxygen are higher in the muscle mitochondria of
UCP3 KO mice [93]. This obviously does not rule
out the possibility of UCP3 having another transport
activity, but this activity seems dispensable or e⁄-
ciently replaced by another gene product since mice
are viable.
5. Prospects
Much future work will focus on the physiology of
KO mice, and should clarify the physiological role of
these proteins. We anticipate several unexpected con-
sequences of this work. Relevant activities could then
be explored further using reconstituted or recombi-
nant expression systems. At this point we hope that
the knowledge accumulated will not only stimulate
debate about the mechanisms of transport across
membranes but also lead to applications bene¢cial
for human health.
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